


## Supplemental Figure 3



**Supplemental Figure 3. Cyto-genetic risk does not significantly affect sensitivity to ROC-325.** Primary AML blasts (N = 5 patients per cyto-genetic risk group) were treated with the indicated concentrations of ROC-325 for 72 h. The impact of drug treatment on cell viability was assessed by MTT assay. Mean  $\pm$  SD.